HIGHLIGHTS
- who: Manuel Olmos from the Department of Oral and Maxillofacial Surgery, Friedrich-Alexander University Erlangen-Nu00fcrnberg (FAU), Erlangen, Germany have published the research: Neoadjuvant Immunotherapy of Oral Squamous Cell Carcinoma: Case Report and Assessment of Histological Response, in the Journal: (JOURNAL)
- how: While the authors await the results of this trial it is expected that the addition of Pembrolizumab will significantly improve pathologic response and event-free survival compared with adjuvant chemoradiotherapy alone. Similar observations were made for PD-L1 expression which drastically increased after neoadjuvant Pembrolizumab application as shown in Figures 3A B. Both . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.